SomaLogic (NASDAQ:SLGC – Get Rating) is one of 41 publicly-traded companies in the "Commercial physical research" industry, but how does it contrast to its rivals? We will compare SomaLogic to related businesses based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, institutional ownership and risk.

Profitability

This table compares SomaLogic and its rivals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for SomaLogic and its rivals, as provided by MarketBeat.

Risk and Volatility

SomaLogic has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, SomaLogic's rivals have a beta of 5.23, suggesting that their average stock price is 423% more volatile than the S&P 500.

Insider & Institutional Ownership

59.3% of SomaLogic shares are owned by institutional investors. Comparatively, 58.4% of shares of all "Commercial physical research" companies are owned by institutional investors. 12.9% of SomaLogic shares are owned by company insiders. Comparatively, 11.9% of shares of all "Commercial physical research" companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares SomaLogic and its rivals gross revenue, earnings per share and valuation.

SomaLogic's rivals have higher revenue and earnings than SomaLogic. SomaLogic is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

SomaLogic beats its rivals on 7 of the 13 factors compared.

SomaLogic Company Profile

(Get Rating)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.